Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 190 participants.

Also called NCT02315287

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 190 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02315287
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02315287. Randomized; triple masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2021-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Lobeglitazone
Lead sponsor
Seoul National University Bundang Hospital (class: other)

Record details

Record id
cardio:ct-nct02315287
Content hash
f7a7db3aaea1d3e86d4a9950d8f2d89fd4c83a200274b85c36d1e5f5bd7d0ae4